undamentalytics Newsletter
Sign in

Bausch & Lomb Corp (BLCO) stock

Add to watchlist

Add holding +

NYSE: BLCO NYSE Health Care Equipment Next results ~February 17, 2027

C+ Fundamentals grade

Bausch & Lomb Corp is a US-listed company in the health care equipment industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

Under review: our cash-flow value ($1.55) was left out of our combined valuation (it is 0.08x the share price, outside the 0.2-5x range we accept), so it can't be the basis of a rating.

Price vs value

Under review: our cash-flow value ($1.55) was left out of our combined valuation (it is 0.08x the share price, outside the 0.2-5x range we accept), so it can't be the basis of a rating. We'll show the comparison once resolved.

Bausch & Lomb Corp valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders9 buying, 2 selling9 purchases and 4 sales by directors and officers, last 12 monthsInsider trades
  • Funds50 adding, 45 cuttingOf 28 active managers that changed their stake, 19 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Bausch & Lomb files

Where Bausch & Lomb stands after its latest 10-Q

Revenue for the twelve months to September 2026 was $5.42bn, up 8.9% on a year earlier, about the same pace as a quarter earlier. Free-cash-flow margin rose to 4.7% from -3.9% a year earlier. Operating margin widened to 7.1% from 1.8%. Against its peers on growth, profitability, cash generation and balance sheet, it grades C+. It passes 1 of our 7 financial-health checks.

Our model value for Bausch & Lomb is under review, so past values are not shown until it is resolved.

Source: 10-Q filed October 28, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~February 17, 2027 (estimated)

Bausch & Lomb Corp's trailing-twelve-month revenue grew 8.9% year on year, with a free-cash-flow margin of 4.7%.

Our discounted-cash-flow model values the business at ~$1.6 per share in the base case (—–$6.2 across growth scenarios) — model values under stated assumptions, not a price target.

Current signal Results well ahead of expectations: Reported earnings per share beat the analysts' consensus estimate by 55% in the quarter to 2026-09-30, the 2nd beat in the last four quarters.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Margins widening. Operating margin is up 5.3 points on a year ago.
  • Estimates rising. Analysts' consensus for next year's earnings per share has risen 10.5% over 90 days.

Things to watch

  • Missing expectations. Earnings per share fell short of the consensus estimate in 2 of the last four quarters.

Latest results: FY2026 Q3

Filed October 28, 2026
Earnings per share
$0.34 against an average estimate of $0.22: beat by 54.7%
Revenue
$1.38bn, up 7.3% on a year earlier
Share reaction
+15.8% in the first session after the results on October 28, 2026, against 0.0% for the S&P 500
Guidance given
full-Year Revenue $5.45bn to $5.55bn (Full-Year 2026); full-Year Revenue Constant Currency Growth growth 6.1% to 8% (Full-Year 2026)
Next report
October 28, 2026; average EPS estimate $0.37

Bausch & Lomb's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day+0.1%
  • 1 week+13.8%
  • 1 month+16.9%
  • This year+17.2%
  • 1 year+33.9%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$5.4B
Operating margin
7.1%
Net margin
-2.0%
EPS (TTM, diluted)
$-0.31

Growth

Revenue growth
+8.9%
Change in growth rate
+0.0 pts
Share count change
+1.2%

Cash

Free cash flow (TTM)
$252M
FCF margin
4.7%
Stock pay % of revenue
3.2%

Earnings

Last results
October 28, 2026
Next results (est.)
February 17, 2027

News & updates

Updated November 3, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Insider trade
  2. Leadership
  3. Results
  4. Guidance
  5. Leadership
  6. Leadership
  7. Results

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Bausch & Lomb Corp valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: held for review: our cash-flow value ($1.55) was left out of our combined valuation (it is 0.08x the share price, outside the 0.2-5x range we accept), so it can't be the basis of a rating.

Our value per share comes from a discounted-cash-flow model of Bausch & Lomb Corp's free cash flow after stock-based pay ( $210M, FY2026 Q3 TTM, with after-tax interest added back): growth for five years as below (the first two years from forecasts, guidance and the company's record), fading to 2.5%, discounted at 8.5%, then cash added and debt and other claims subtracted. These are model values under stated assumptions, not price targets or recommendations.

The inputs used by the models below have passed source checks. Individual model values are available below and in the interactive valuator. Their differences are shown explicitly; the platform combined value and recommendation remain withheld.

Valuation models

We value Bausch & Lomb Corp as an operating company, with every model that fits that kind of business. Cost of equity 9.3%: the 10-year Treasury yield (4.9%) plus a beta of 0.96 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Cash-flow model (DCF) Free cash flow to the firm (after stock pay, with after-tax interest added back), grown then faded to 2.5%, discounted at 8.5% as the firm rate, less debt and other claims. ~$1.6 Left out: out of range vs price (0.08x)
Forward price-to-earnings vs peers Next year's consensus earnings per share times peers' typical (harmonic-mean) forward price-to-earnings. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$20 ~$17–$32 Included
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. ~$0.8 ~$0.2–$2.0 Left out: out of range vs price (0.04x)
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: This model is withheld pending its input or assumption review.
Combined value Individual source-checked model scenarios are available. The platform combined value and recommendation remain withheld. — Combined value withheld. Review the individual models and their assumptions.

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Bausch & Lomb Corp with Health Care Equipment in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 2022202320242025Now
Share price$15.51$17.06$18.06$17.08$20.01
Market value$5.4bn$6.0bn$6.4bn$6.0bn$7.1bn
+ Net debt (− = net cash)$2.1bn$4.3bn$4.5bn$4.7bn$4.6bn
Enterprise value$7.6bn$10.3bn$10.9bn$10.8bn$11.7bn
Multiples
Price / sales 1.4x1.4x1.3x1.2x1.3x
Price / earnings n/m————
Price / free cash flow 32.0x———28.4x
EV / EBITDA 12.9x20.1x18.2x20.2x14.9x

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

19 /100

Weak moat

How hard Bausch & Lomb's competitive advantage looks for rivals to wear away, judged from 5 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Net income has been a median -1.6% of total assets over 5 years.

  • Durability 8 / 20

    Operating margin has been a median 3.3%; its worst year was 1.8%.

  • Cash conversion 4 / 20

    Free cash flow was positive in 2 of 5 years, at a median -0.5% of revenue.

AI disruption exposure: Low. In this industry, the business rests on physical assets, regulated networks or products AI itself depends on.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current $0.95 +86% $5.5bn +8%
Next $1.19 +26% $5.8bn +6%

Next year's EPS estimate has moved +10.5% in 90 days, across 14 analysts.

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is +18.1% on 90 days ago. In the last 30 days, 1 analyst raised Bausch & Lomb Corp's forecast and 0 cut it.

Consensus EPS forecast Bausch & Lomb Corp, last 90 days
$0.80 $0.90 $1.00 $1.10 $1.20 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: $0.80 Current fiscal year, 60 days ago: $0.80 Current fiscal year, 30 days ago: $0.81 Current fiscal year, 7 days ago: $0.81 Current fiscal year, Now: $0.95 $0.95 Next fiscal year, 90 days ago: $1.08 Next fiscal year, 60 days ago: $1.09 Next fiscal year, 30 days ago: $1.11 Next fiscal year, 7 days ago: $1.11 Next fiscal year, Now: $1.19 $1.19

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago $0.80$1.08
60 days ago $0.80$1.09
30 days ago $0.81$1.11
7 days ago $0.81$1.11
Now $0.95$1.19

Earnings against estimates

Quarter toEstimateActualSurprise
Sept 2026 $0.22 $0.34 +54.7%
Jun 2026 $0.16 $0.16 −0.3%
Mar 2026 $0.05 $0.08 +49.2%
Dec 2025 $0.36 $0.32 −10.3%

Adjusted EPS as companies report it, against the average analyst estimate.

Management guidance

Earnings release, October 28, 2026
  • Full-Year Revenue Full-Year 2026 $5.45bn to $5.55bn GAAP Raised
    “Full-Year Revenue • $5.440B - $5.540B • $5.450B - $5.550B” source
  • Full-Year Revenue Constant Currency Growth Full-Year 2026 6.1% growth to 8% growth Non-GAAP Raised
    “• 5.8 - 7.7% constant currency growth 1 • 6.1 - 8.0% constant currency growth 1” source
  • Full-Year Adjusted EBITDA Excluding Acquired IPR&D (non-GAAP) Full-Year 2026 $1.09bn to $1.14bn Non-GAAP Raised
    “Full-Year Adjusted EBITDA Excluding Acquired IPR&D (non-GAAP) 1 • $1.025B - $1.075B • $1.090B - $1.140B” source
  • Full-Year Revenue Foreign Exchange Tailwinds Full-Year 2026 about $40m Lowered
    “Full-Year Revenue Foreign Exchange Tailwinds • $45M • $40M” source

Figures and quotations are management's, copied from the company's own press release (SEC 8-K exhibit) and checked word for word against it. Forward-looking statements are the company's expectations, not ours and not advice; guidance can change or be missed.

How our valuation uses these forecasts

Our cash-flow model grows Bausch & Lomb Corp's revenue by +6.8% next year and +8.5% the year after, then fades back toward its own record by year five. Next year's rate weighs analysts' consensus (+6.0%, weight 46%) , management guidance (+6.0%, weight 32%) and the company's own record (+9.9%, weight 21%) . How the weights are set.

Analyst recommendations

15 analysts, Oct 2026
Buy747%
Hold747%
Sell17%

Monthly trend

  1. Oct 202625715
  2. Sep 2026157114
  3. Aug 2026147113
  4. Jul 2026147113

Counts of recommendations published by analysts covering Bausch & Lomb Corp, by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
5.5%
of tradable shares
Days to cover
5.12
at average volume
Short interest, 1 month
−20%
to October 15, 2026
Held by institutions
11%
of shares
Held by insiders
87.3%
of shares
Employees
13,000
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

What moved the share price

Last 12 months +33.9%

$14.94 on October 31, 2025 to $20.01

ThenNowEffect
Revenue (last 12 months) $4.9bn $5.3bn +8.9%
P/S multiple 1.1x 1.3x +23.9%
Share count 353m 355m −0.7%

Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.

Last 3 years +16.7%

$17.14 on November 3, 2023 to $20.01

ThenNowEffect
Revenue (last 12 months) $3.9bn $5.3bn +36.4%
P/S multiple 1.5x 1.3x −13.2%
Share count 350m 355m −1.4%

Biggest factor: revenue. Loss-making at one end, so the split uses price/sales.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 2023202420252026 to date
Return
BLCO+10%+6%−5%+17%
Industry peers (median)−9%−20%−16%−15%
S&P 500+26%+25%+18%+11%
Months that ended higher
BLCO50%50%50%55%
S&P 50067%75%75%46%
Largest fall from a high during the year
BLCO−29%−23%−40%−20%
S&P 500−10%−8%−19%−9%

Worst fall since May 6, 2022: 48% from July 13, 2023 to May 6, 2025. Getting back needed a 93% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$14.56 – $20.40
From 52-week high
−1.9%
vs 50-day average
+15.0%
vs 200-day average
+19.9%
Volatility (1 year)
33%
Beta vs S&P 500
0.97

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
4 up, 8 down
typical move ±5.9%
After a week
6 up, 5 down
typical move ±6.0%
After a month
4 up, 7 down
typical move ±5.9%
Results releasedNext dayS&P 500 next day5 days21 days
October 28, 2026 +15.8% 0.0% — —
July 29, 2026 +2.3% +0.1% +0.9% +3.1%
April 29, 2026 +1.1% +1.0% +1.8% −0.4%
February 18, 2026 −0.5% +0.2% +4.9% −8.8%
October 29, 2025 −0.4% −1.1% +3.5% +6.5%
July 30, 2025 −7.0% −0.5% −3.7% −0.7%
April 30, 2025 −15.5% +0.7% −16.9% −16.4%
February 19, 2025 −2.8% −0.2% −3.0% −3.7%
October 30, 2024 −2.3% −2.3% −4.5% −4.5%
July 31, 2024 −0.1% +0.2% −9.4% −5.2%
May 1, 2024 −4.7% +0.6% +1.9% +5.5%
February 21, 2024 +18.7% +2.2% +15.5% +10.2%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Bausch & Lomb Corp in five measures

Fundamentals grade C+
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Bausch & Lomb Corp
$4B $4.5B $5B $5.5B FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 Revenue (TTM), FY23 Q4: $4.1B Revenue (TTM), FY24 Q1: $4.3B Revenue (TTM), FY24 Q2: $4.5B Revenue (TTM), FY24 Q3: $4.7B Revenue (TTM), FY24 Q4: $4.8B Revenue (TTM), FY25 Q1: $4.8B Revenue (TTM), FY25 Q2: $4.9B Revenue (TTM), FY25 Q3: $5B Revenue (TTM), FY25 Q4: $5.1B Revenue (TTM), FY26 Q1: $5.2B Revenue (TTM), FY26 Q2: $5.3B Revenue (TTM), FY26 Q3: $5.4B $5.4B

Source: SEC EDGAR filings. Retrieved October 31, 2026.

View chart data
Period Revenue (TTM)
FY23 Q4 $4.1B
FY24 Q1 $4.3B
FY24 Q2 $4.5B
FY24 Q3 $4.7B
FY24 Q4 $4.8B
FY25 Q1 $4.8B
FY25 Q2 $4.9B
FY25 Q3 $5B
FY25 Q4 $5.1B
FY26 Q1 $5.2B
FY26 Q2 $5.3B
FY26 Q3 $5.4B
Revenue growth, TTM YoY Bausch & Lomb Corp
0% 5% 10% 15% 20% FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 Revenue growth, TTM YoY, FY23 Q4: 10.0% Revenue growth, TTM YoY, FY24 Q1: 13.2% Revenue growth, TTM YoY, FY24 Q2: 15.1% Revenue growth, TTM YoY, FY24 Q3: 18.0% Revenue growth, TTM YoY, FY24 Q4: 15.6% Revenue growth, TTM YoY, FY25 Q1: 11.9% Revenue growth, TTM YoY, FY25 Q2: 8.8% Revenue growth, TTM YoY, FY25 Q3: 6.2% Revenue growth, TTM YoY, FY25 Q4: 6.5% Revenue growth, TTM YoY, FY26 Q1: 7.8% Revenue growth, TTM YoY, FY26 Q2: 8.9% Revenue growth, TTM YoY, FY26 Q3: 8.9% 8.9%

Source: SEC EDGAR filings. Retrieved October 31, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q4 10.0%
FY24 Q1 13.2%
FY24 Q2 15.1%
FY24 Q3 18.0%
FY24 Q4 15.6%
FY25 Q1 11.9%
FY25 Q2 8.8%
FY25 Q3 6.2%
FY25 Q4 6.5%
FY26 Q1 7.8%
FY26 Q2 8.9%
FY26 Q3 8.9%
Operating margin (TTM) Bausch & Lomb Corp
0% 2% 4% 6% 8% FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 Operating margin (TTM), FY23 Q4: 3.1% Operating margin (TTM), FY24 Q1: 3.2% Operating margin (TTM), FY24 Q2: 2.7% Operating margin (TTM), FY24 Q3: 2.6% Operating margin (TTM), FY24 Q4: 3.4% Operating margin (TTM), FY25 Q1: 1.5% Operating margin (TTM), FY25 Q2: 0.7% Operating margin (TTM), FY25 Q3: 1.8% Operating margin (TTM), FY25 Q4: 2.2% Operating margin (TTM), FY26 Q1: 4.4% Operating margin (TTM), FY26 Q2: 6.1% Operating margin (TTM), FY26 Q3: 7.1% 7.1%

Source: SEC EDGAR filings. Retrieved October 31, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q4 3.1%
FY24 Q1 3.2%
FY24 Q2 2.7%
FY24 Q3 2.6%
FY24 Q4 3.4%
FY25 Q1 1.5%
FY25 Q2 0.7%
FY25 Q3 1.8%
FY25 Q4 2.2%
FY26 Q1 4.4%
FY26 Q2 6.1%
FY26 Q3 7.1%
FCF margin (TTM) Bausch & Lomb Corp
-5% 0% 5% FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 FCF margin (TTM), FY23 Q4: -4.8% FCF margin (TTM), FY24 Q1: -3.0% FCF margin (TTM), FY24 Q2: -3.0% FCF margin (TTM), FY24 Q3: -1.2% FCF margin (TTM), FY24 Q4: -1.2% FCF margin (TTM), FY25 Q1: -3.5% FCF margin (TTM), FY25 Q2: -3.4% FCF margin (TTM), FY25 Q3: -3.9% FCF margin (TTM), FY25 Q4: -1.3% FCF margin (TTM), FY26 Q1: 0.0% FCF margin (TTM), FY26 Q2: 2.6% FCF margin (TTM), FY26 Q3: 4.7% 4.7%

Source: SEC EDGAR filings. Retrieved October 31, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q4 -4.8%
FY24 Q1 -3.0%
FY24 Q2 -3.0%
FY24 Q3 -1.2%
FY24 Q4 -1.2%
FY25 Q1 -3.5%
FY25 Q2 -3.4%
FY25 Q3 -3.9%
FY25 Q4 -1.3%
FY26 Q1 0.0%
FY26 Q2 2.6%
FY26 Q3 4.7%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Sept 2026
Income
Revenue 3,412 3,765 3,768 4,146 4,791 5,101 5,418
EBITDA 702 744 586 512 598 534 787
Operating income 260 329 207 130 162 113 383
Net income −18 182 6 −260 −317 −360 −111
Diluted EPS −$0.05 $0.52 $0.02 −$0.74 −$0.90 −$1.02 −$0.31
Growth (year on year)
Revenue — +10.3% +0.1% +10.0% +15.6% +6.5% +8.9%
EBITDA — +6.0% −21.2% −12.6% +16.8% −10.7% +52.5%
Operating income — +26.5% −37.1% −37.2% +24.6% −30.2% —
Net income — — −96.7% — — — —
Diluted EPS — — −96.2% — — — —
Margins
EBITDA margin 20.6% 19.8% 15.6% 12.3% 12.5% 10.5% 14.5%
Operating margin 7.6% 8.7% 5.5% 3.1% 3.4% 2.2% 7.1%
Net margin −0.5% 4.8% 0.2% −6.3% −6.6% −7.1% −2.0%
Free-cash-flow margin 7.9% 18.1% 4.5% −4.8% −1.2% −1.3% 4.7%
Cash flow
Cash from operations 522 873 345 −17 232 283 554
Capital spending 253 193 175 181 291 349 302
Free cash flow 269 680 170 −198 −59 −66 252
Stock-based pay 50 62 62 74 92 149 173
Free cash flow after stock pay 219 618 108 −272 −151 −215 79
Balance sheet
Cash 238 174 354 331 305 383 513
Total debt 0 0 2,488 4,636 4,841 5,107 5,065
Net debt (negative = net cash) −238 −174 2,134 4,305 4,536 4,724 4,552
Diluted shares 350m 350m 350m 351m 352m 354m 357m

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

1 of 7 checks passed · September 30, 2026
What it owns · $14.0bn
Short-term assets $3.1bnLonger-term assets $10.9bn
What it owes, and who funded it · $13.9bn
Short-term liabilities $2.0bnLonger-term liabilities $5.5bnShareholders' equity $6.4bn
  • Short-term assets cover short-term liabilities $3.1bn of assets due within a year against $2.0bn of liabilities due within a year.
  • Short-term assets cover long-term liabilities $3.1bn short-term assets against $5.5bn of longer-dated liabilities.
  • More cash than debt $513m of cash against $5.0bn of debt.
  • Debt below 40% of shareholders' equity Debt is 78% of equity.
  • Debt burden no higher than five years ago Debt to equity moved from 0% to 78% over five years.
  • A year's operating cash flow covers at least 20% of debt $554m of operating cash flow against $5.0bn of debt.
  • Operating profit covers interest at least five times over Operating income of $383m against $383m of interest.

From Bausch & Lomb Corp's latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Diluted share count
+1.2%
year over year
R&D spending
7.4%
of revenue
Sales & admin spending
41.6%
of revenue

Competitors: side by side with peers

Closest by revenue in health care equipment
Last 12 months unless stated BLCO RMD DXCM STE IDXX EW Median
Revenue, last 12 months $5.4bn $5.7bn $5.1bn $6.0bn $4.7bn $6.5bn $99m
Revenue growth, last 12 months 8.9% 9.0% 13.0% 8.4% 11.9% 14.6% 9.2%
Revenue growth, 3-year average 10.9% 9.4% 14.5% 9.0% 9.1% 15.3% 13.5%
Revenue growth, latest quarter 7.3% 5.9% 11.2% 7.3% 9.9% 13.6% 10.2%
Gross margin — 61.1% 63.4% 44.4% 62.7% 77.8% 61.2%
Operating margin 7.1% 33.0% 24.0% 18.9% 32.3% 22.3% −8.5%
Operating margin, 3-year average 3.8% 31.9% 19.0% 17.1% 30.9% 25.2% −17.9%
Net margin −2.0% 27.8% 19.4% 13.3% 25.4% 15.4% −12.0%
Cash from operations / revenue 10.2% 30.9% 27.7% 21.3% 30.4% 26.4% −1.9%
Free-cash-flow margin 4.7% 28.1% 21.5% 15.3% 28.0% 22.0% −3.9%
Free-cash-flow margin, 3-year average −0.2% 29.9% 19.5% 14.3% 23.9% 14.4% −7.0%
Stock pay / revenue 3.2% 2.0% 3.0% 1.0% 1.4% 2.6% 6.1%
Change in share count 1.2% −1.3% −3.9% −0.5% −2.2% −1.6% 4.0%

Median of all 134 companies we cover in health care equipment. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

134 health care equipment companies
Measure Company Peer median Rank
Revenue growth Growth 8.9% 9.1% 68 of 129
Change in growth rate Growth +0.0pp -0.6pp 56 of 129
Operating margin Profitability 7.1% -8.3% 38 of 132
Net margin Profitability -2.0% -12.0% 48 of 133
Free-cash-flow margin Cash generation 4.7% -3.4% 43 of 128
Stock pay as % of revenue Cash generation 3.2% 6.1% 42 of 123
Long-term debt as % of assets Balance sheet 35.7% 24.2% 65 of 87
Change in share count Balance sheet 1.2% 3.3% 42 of 115

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Where the revenue comes from

Fiscal year to December 31, 2025
Segments
Line of business Revenue Share YoY
Vision Care $2.9B 57.3% ▲ 6.7%
Pharmaceuticals $1.3B 25.2% ▲ 6.2%
Surgical $894M 17.5% ▲ 6.0%
Products and services
Line of business Revenue Share YoY
Products $5.1B 99.2% ▲ 6.4%
Device Products $1.9B 37.8% ▲ 6.8%
Overthe Counter Products $1.8B 36.1% ▲ 6.4%
Pharmaceutical Products $1.1B 21.3% ▲ 11.6%
Branded and Other Generic Products $243M 4.8% ▼ 13.5%
Other $21M 0.4% ▲ 23.5%
Other Revenues $21M 0.4% ▲ 23.5%
Geography
Region Revenue Share YoY
United States and Puerto Rico $2.5B 49.9% ▲ 5.5%
Other Countries $777M 15.2% ▲ 9.1%
China $358M 7.0% 0.0%
France $246M 4.8% ▲ 8.4%
Japan $186M 3.6% ▲ 3.3%
Germany $164M 3.2% ▲ 7.9%
RU $148M 2.9% ▲ 23.3%
United Kingdom $137M 2.7% ▲ 3.8%
Canada $135M 2.6% ▲ 6.3%
IT $102M 2.0% ▲ 12.1%
ES $101M 2.0% ▲ 9.8%
Mexico $75M 1.5% 0.0%
PL $75M 1.5% ▲ 15.4%
South Korea $51M 1.0% ▲ 8.5%

From Bausch & Lomb Corp's 10-K filed February 18, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$632M
Institutions reporting
98
Shares held vs prior quarter
▲ 0.5%
Positions opened / closed
19 / 15

Top buyers and sellers, Q2 2026: 50 institutions bought and 45 sold ; the biggest buyer was Davidson Kempner Capital Management LP (+960K shares) and the biggest seller Silver Point Capital L.P (−2.2M). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Icahn Carl C $58M 3.5M 9.2% 0.0%
Oaktree Capital Management LP $57M 3.4M 9.0% ▲ 1.7%
Deutsche Bank Ag\ $56.7M 3.4M 9.0% ▼ 3.0%
D. E. Shaw & Co., Inc. $55M 3.3M 8.7% ▲ 5.5%
Davidson Kempner Capital Management LP $52.3M 3.2M 8.3% ▲ 43.6%
Goldentree Asset Management LP $44M 2.7M 7.0% 0.0%
Price T Rowe Associates Inc $35.8M 2.2M 5.7% ▲ 76.5%
Caspian Capital LP $33.1M 2.0M 5.2% 0.0%
Glenview Capital Management, LLC $31.8M 1.9M 5.0% ▲ 0.4%
Arrowstreet Capital, Limited Partnership $22.6M 1.4M 3.6% ▲ 39.0%
Citadel Advisors LLC $16.4M 988K 2.6% ▲ 40.1%
Clark Estates Inc $14.6M 881K 2.3% ▲ 6.8%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Bausch & Lomb Corp's complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $1.2M 9 trades by 9 insiders, last 12 months Insider sales History → $3.5M 4 trades by 2 insiders · 0% under pre-set plans
Net ▼ $2.3M net selling
Insider Date Trade Shares Price Value
Munsch Frederick SVP, Controller and CAO October 29, 2026 Sell 112,015 $20.48 $2.3M
Munsch Frederick SVP, Controller and CAO August 10, 2026 Sell 52,900 $16.78 $887,662
Von Eschenbach Andrew C. Director August 7, 2026 Sell 6,059 $16.58 $100,458
Von Eschenbach Andrew C. Director August 6, 2026 Sell 12,500 $16.50 $206,250
Saunders Brent L CEO and Chairman of the Board March 6, 2026 Buy 14,700 $17.14 $251,958
Eldessouky Sam EVP and CFO March 6, 2026 Buy 4,000 $17.13 $68,520
Bailey A Robert D EVP & Chief Legal Officer March 6, 2026 Buy 14,600 $17.15 $250,390
Ross Thomas W. Sr. Director March 3, 2026 Buy 4,500 $17.68 $79,560
Alfonso Eduardo Director March 2, 2026 Buy 4,300 $17.90 $76,970
Von Eschenbach Andrew C. Director February 27, 2026 Buy 4,364 $18.31 $79,905
Collis Steven H Director February 23, 2026 Buy 15,000 $17.81 $267,150
Robertson Russel C Director February 20, 2026 Buy 4,400 $17.90 $78,760

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around February 17, 2027 estimated from the company's past filing pattern, not announced

  • October 28, 2026
  • July 29, 2026
  • April 29, 2026
  • February 18, 2026
  • October 29, 2025
  • July 30, 2025

Recent SEC filings

Data status

When each part of this page on Bausch & Lomb Corp was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Bausch & Lomb Corp in brief

What does Bausch & Lomb Corp do?
Bausch & Lomb Corp is a US-listed company in the health care equipment industry. Its financial year ends in December.
What is Bausch & Lomb Corp's stock ticker?
Bausch & Lomb Corp trades under the ticker BLCO on NYSE. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Bausch & Lomb Corp's revenue, and how fast is it growing?
Over its most recent trailing twelve months, Bausch & Lomb Corp reported revenue of $5.4B, 8.9% higher than a year earlier, according to its SEC filings.
What is Bausch & Lomb Corp's free cash flow?
Bausch & Lomb Corp's free-cash-flow margin is 4.7% of revenue over the trailing twelve months, ranking 43 of the 128 health care equipment companies we cover.
Who are Bausch & Lomb Corp's largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Icahn Carl C, Oaktree Capital Management LP and Deutsche Bank Ag\. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Bausch & Lomb Corp's market cap?
On November 2, 2026, Bausch & Lomb Corp's market capitalisation was about $7.1B and net debt of $4.6B. Market figures come from third-party market data and may be delayed.
How much debt does Bausch & Lomb Corp have?
Bausch & Lomb Corp's debt-to-equity ratio is 77.9%, from its latest balance sheet (0.0% five years earlier). The financial health section below sets out its other solvency checks.
Who are Bausch & Lomb Corp's competitors?
In our Health Care Equipment peer group, the companies closest to Bausch & Lomb Corp are ResMed|, Dexcom, Steris, Idexx Laboratories and Edwards Lifesciences. The side-by-side comparison below sets their revenue, margins and growth against Bausch & Lomb Corp's.
Are insiders buying or selling Bausch & Lomb Corp stock?
Over the last 12 months, Bausch & Lomb Corp's directors and officers reported 9 open-market purchases and 4 sales on Form 4. The insider trading page charts every trade.
When is Bausch & Lomb Corp's next earnings date?
Around February 17, 2027, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Bausch & Lomb Corp announces its own schedule.